Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378444 | 1.00 | NPC1 (0.54) | NPC1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL8698369 | 0.84 | ALDH1A1 (0.47) | NPC1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL9619788 | 0.82 | SMN1; SMN2 (0.52) | KMT2AMEN1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8854027 | 0.81 | TSHR (0.45) | NPC1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL13645822 | 0.80 | NPC1 (0.56) | NPC1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL16602097 | 0.80 | NPC1 (0.56) | NPC1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL8310016 | 0.80 | NPC1 (0.56) | NPC1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3379479 | 0.80 | PPARG (0.54) | NPC1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL3379484 | 0.80 | PPARG (0.54) | NPC1KMT2AMEN1MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL30140874 | 0.79 | NPC1 (0.55) | NPC1KMT2AMEN1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101389609-B | Hydantoin-based kinase inhibitors | HOFFMANN LA ROCHE | 2012-01-11 | — | — | CN | disclosed |
| EP-1989186-B1 | HYDANTOIN BASED KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7612212-B2 | 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| CN-101389609-A | Hydantoin-based kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-03-18 | — | — | CN | disclosed |
| EP-1989186-A1 | HYDANTOIN BASED KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008101840-A1 | COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | NIU HUIFENG | 2008-08-28 | — | — | US | disclosed |
| WO-2007096259-A1 | HYDANTOIN BASED KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
| US-RE33948-E | Bactericides, animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
| US-4748163-A | Novel β-lactam antibiotics | BAYER AKTIENGESELLSCHAFT (DE) | 1988-05-31 | — | — | US | disclosed |
| EP-0195947-A2 | Beta-lactam antibiotics, process for their preparation and their use as and in medicaments | BAYER AG (DE) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | NPC1 2469/4885KMT2A 179/4885MEN1 444/4885 |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | MKI67, BRAF, MYC | NPC1 3225/4885KMT2A 1913/4885MEN1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.